⌘K
OverviewStock screenerAnalyst actionsCalendar
MarketsInvestorsSign in
StockUnited StatesNasdaqCM

LQDA

Liquidia Corporation

Healthcare · Drug Manufacturers - Specialty & Generic

69.12USD

+1.4400 (+2.13%)

DescriptionHistoricalFinancialsRelative ValueResearchNewsDiscussionOptionsPrice Chart ↗Fundamental Chart ↗

Estimates and surprises

Consensus EPS on the street’s adjusted basis, not the filed GAAP figure — which is why the actuals here can differ from the income statement.

PeriodConsensus EPS90 days agoRevisions up (30d)Revisions down (30d)
Current quarter$0.96▼$0.9714
Next quarter$1▼$1.1513
Current year$3.22▼$3.4805
Next year$5.65▲$5.5732

Recent quarters

Beat in 2 of the last 4

QuarterEstimateActualSurprise
2026-06-30$0.84$0.74-0.10 (-11.5%)
2026-03-31$0.41$0.52+0.11 (+28.1%)
2025-12-31$0.33$0.15-0.18 (-55.1%)
2025-09-30$-0.35$-0.04+0.31 (+88.7%)

Wall Street coverage

55 ratings from 10 firms

Ratings are attributed to the research firm, not to individual analysts. See every ticker.

FirmActionRatingPrice TargetDate
ScotiabankInitiatedSector Outperform$30Oct 16, 2024
LifeSci CapitalInitiatedOutperform$30Oct 3, 2024
HC Wainwright & Co.ReiteratedBuy$29Aug 23, 2024
NeedhamReiteratedBuy$19Aug 22, 2024
BTIGMaintainedBuy$29 $25Aug 20, 2024
B of A SecuritiesMaintainedBuy$24 $23Aug 20, 2024
HC Wainwright & Co.MaintainedBuy$32 $29Aug 20, 2024
BTIGMaintainedBuy$29 $25Aug 19, 2024
Raymond JamesUpgraded from OutperformStrong Buy$27Aug 19, 2024
NeedhamReiteratedBuy$25Aug 19, 2024
Raymond JamesInitiatedOutperform$27Aug 16, 2024
NeedhamReiteratedBuy$25Aug 13, 2024
NeedhamMaintainedBuy$28 $25Aug 8, 2024
NeedhamReiteratedBuy$28Jul 18, 2024
HC Wainwright & Co.ReiteratedBuy$32Jul 10, 2024
OppenheimerInitiatedPerform—Jun 25, 2024
NeedhamReiteratedBuy$28Jun 3, 2024
HC Wainwright & Co.ReiteratedBuy$32May 15, 2024
NeedhamReiteratedBuy$28May 15, 2024
NeedhamReiteratedBuy$28Apr 10, 2024
NeedhamReiteratedBuy$28Apr 1, 2024
HC Wainwright & Co.MaintainedBuy$16 $32Mar 14, 2024
NeedhamMaintainedBuy$28Mar 13, 2024
NeedhamReiteratedBuy$28Feb 21, 2024
NeedhamMaintainedBuy$18 $28Jan 5, 2024

Insider transactions

156 filings from 19 insiders · 34 buy / 59 sell over 6m

Officers and directors of LQDA, from the last two years of filings. Grants, gifts and option exercises are shown but not colour-coded — they are compensation, not a view on the price.

InsiderActionSharesPriceValueDate
Krepp SarahOfficer, Chief Human Resource OfficerSell274$67.76$19kSep 1, 2026
ADAIR JASONOfficerSell73.6k$69.09$5.09MAug 21, 2026
ADAIR JASONOfficerExercise31.8k$9.31$350kAug 21, 2026
RIELLY-GAUVIN KATHERINEDirectorSell55.2k$72.23$4.09MAug 20, 2026
RIELLY-GAUVIN KATHERINEDirectorExercise55.2k$2.51$140kAug 20, 2026
SAGGAR RAJEEVOfficerExercise50.0k$3.73$187kAug 19, 2026
SAGGAR RAJEEVOfficerSell79.5k$74.06$5.97MAug 19, 2026
BOYLE DANAOfficerSell1.6k$87.53$140kJul 27, 2026
ADAIR JASONOfficerSell688$87.53$60kJul 27, 2026
BLOCH STEPHEN M.DirectorSellindirect200.0k$87.70$17.79MJul 23, 2026
BLOCH STEPHEN M.DirectorSellindirect78.6k$79.55$6.29MJul 21, 2026
BOYLE DANAOfficerSell9.0k$71.39$644kJul 13, 2026
KHINDRI SANJEEVOfficerSell1.2k$71.39$85kJul 13, 2026
ADAIR JASONOfficerSell7.9k$71.39$562kJul 13, 2026
MOOMAW SCOTTOfficerSell9.5k$71.39$682kJul 13, 2026
SCHUNDLER RUSSELLGeneral CounselSell14.7k$71.39$1.05MJul 13, 2026
SAGGAR RAJEEVOfficerSell9.9k$71.39$710kJul 13, 2026
KREPP SARAH TOfficerSell7.9k$71.39$562kJul 13, 2026
JEFFS ROGER AChief Executive OfficerSell35.2k$71.39$2.52MJul 13, 2026
KASETA MICHAELChief Operating OfficerSell20.4k$71.39$1.46MJul 13, 2026

Analyst Notes

Sign in to write

No analyst notes on LQDA yet.

Analyst Ratings

8 analysts covering

PeriodStrong BuyBuyHoldSellStrong SellConsensus
Current15200Buy2.13
1 mo ago15200Buy2.13
2 mo ago16100Buy2.00
3 mo ago16100Buy2.00
Price target$107.75$90.00 – $130.00
+55.9% to target